

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Jacques F. BANCHEREAU

Mail Stop: Amendment

U.S. Application No.: 10/042,644

Group Art Unit: 1646

Filing or 371(c) Date: January 8, 2002

Examiner: Gyan Chandra

Title: Methods for Treating Autoimmune Diseases  
in a Subject and In Vitro Diagnostic Assays

Confirmation No.: 7691

**NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. A copy of each of the documents cited and required by 37 C.F.R. § 1.98 is enclosed.

To assist the Examiner, the documents are listed on the attached form PTO/SB/08. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

The file history of U.S. Patent No. 5,888,511 to Skurkovich et al. has been listed herein. As noted in the Amendment filed concurrently herewith, the following pharmaceutical claim was submitted during prosecution of Skurkovich et al. in the Preliminary Amendment dated December 22, 1997 (see page 5):

33. (Amended) A pharmaceutical composition [comprising an effective amount to treat] for treatment of a patient [with] having an autoimmune disease, said composition comprising an effective amount of one or more components selected from the group consisting of [: antibodies] an antibody to gamma interferon, [antibodies] an antibody to gamma interferon receptor, gamma interferon receptor, [antibodies] an antibody to alpha interferon, an antibody to to alpha interferon receptor, alpha interferon receptor, an autoimmune inhibitor, and a pharmaceutically acceptable carrier therefor.

This Information Disclosure Statement is being submitted after the period specified in 37 C.F.R. § 1.97(b). Therefore, please charge the fee of \$180.00 as required by 37 C.F.R. § 1.97(c). Consideration of the information provided herein is respectfully requested.

**The Director is hereby authorized to charge any appropriate fees that may be required by this paper, and to credit any overpayment, to Deposit Account No. 50-3218.**

Respectfully submitted,

HUTCHISON LAW GROUP PLLC

Date: December 27, 2007

By: Joshua T. Elliott

Joshua T. Elliott

Registration No. 43,603

P.O. Box 31686  
Raleigh, NC 27612  
+1.919.829.9600  
217722